Race Oncology Ltd logo

Race Oncology Ltd

NEW
ASX:RAC (Australia)  
A$ 1.15 +0.020 (+1.77%) Mar 28
At Loss
P/B:
9.66
Market Cap:
A$ 199.78M ($ 125.50M)
Enterprise V:
A$ 181.00M ($ 113.70M)
Volume:
77.23K
Avg Vol (2M):
100.98K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
77.23K
At Loss
Avg Vol (2M):
100.98K

Business Description

Description
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.96
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 20.59
Quick Ratio 20.59
Cash Ratio 20.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.8
Shareholder Yield % -2.72
Name Current Vs Industry Vs History
ROE % -38.62
ROA % -36.46
ROIC % -326.26
3-Year ROIIC % 788.77
ROC (Joel Greenblatt) % -362.43
ROCE % -68.74

Financials

ASX:RAC's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Race Oncology Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.046
Beta 1.07
3-Year Sharpe Ratio -0.23
3-Year Sortino Ratio -0.37
Volatility % 82.09
14-Day RSI 50.08
14-Day ATR (A$) 0.07808
20-Day SMA (A$) 1.114
12-1 Month Momentum % -19.72
52-Week Range (A$) 0.95 - 2.09
Shares Outstanding (Mil) 173.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Race Oncology Ltd Filings

Filing Date Document Date Form
No Filing Data

Race Oncology Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Race Oncology Ltd Frequently Asked Questions

What is Race Oncology Ltd(ASX:RAC)'s stock price today?
The current price of ASX:RAC is A$1.15. The 52 week high of ASX:RAC is A$2.09 and 52 week low is A$0.95.
When is next earnings date of Race Oncology Ltd(ASX:RAC)?
The next earnings date of Race Oncology Ltd(ASX:RAC) is .
Does Race Oncology Ltd(ASX:RAC) pay dividends? If so, how much?
Race Oncology Ltd(ASX:RAC) does not pay dividend.

Press Release

Subject Date
No Press Release